Young child with Doctor

Here in our Media Centre you will find corporate press releases and other useful information for business and financial media

Latest press releases

AstraZeneca strengthens partnership with the University of Cambridge
16 October 2014
Positive results from Phase IIb benralizumab study in severe asthma published in The Lancet Respiratory Medicine
9 October 2014
AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress
27 September 2014
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation
26 September 2014
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label
26 September 2014
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
25 September 2014
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes
19 September 2014
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
16 September 2014
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
16 September 2014
AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes
10 September 2014
Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine
8 September 2014
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
1 September 2014

Fast facts

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.


Sign up to email alerts

Your email address will only be used to provide you with services from AstraZeneca that you requested. You can opt out for email subscriptions any time. Your personal information will not be provided to any third party without your permission.